What drugs are cash traps? The truth is, most companies don't know. But a product portfolio analysis can reveal where resources are best directed—and where it's time to pull the plug. Mar 1, 2006 By:Blair Gibson
Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio.